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doi:10.1016/j.ejvs.2011.03.004Abstract Purpose: To clarify the outcome of aortorenal bypass (ARB) in Takayasu arteritis-
induced renal artery stenosis (TARAS).
Methods: A retrospective chart review was conducted on thirty-three consecutive patients (24
females; mean age, 25 years) with TARAS, who underwent ARB with autologous saphenous vein
graft. The effects on blood pressure and renal function were analyzed. Primary, primary as-
sisted, and secondary patency rates were counted. The effects of various factors on primary
patency rate were analyzed.
Results: All patients showed severe hypertension (mean BP, 175  26/100  19 mm Hg; mean
anti-hypertensive dosage, 2.1  0.6 DDD). Mean estimated glomerular filtration rate was
78  5.1 ml/min. One patient was dialysis-dependent, and three patients had congestive heart
failure secondary to left-ventricular dysfunction. ARB was performed for the 39 renal arteries,
including 27 unilateral and 6 bilateral bypasses. Postoperative morbidity was 15%. All patients
survived. During follow-up (mean, 56 months), two graft occlusions and four graft restenosis
occurred. All graft restenosis were eliminated successfully with percutaneous angioplasty, but
one patient experienced restenosis again six months later. At 1, 3, and 5 years of follow-up,
primary patency was 92%, 89%, and 79%, respectively; primary assisted patency was 95%, 95%,
and 91%, respectively; and secondary patency was 95%, 95%, and 91%, respectively. ARB resulted
in a decrease in mean BP to 139  15/85  13 mm Hg at one month (P < .05) and 136  19/
80  8 mm Hg at last follow-up (P < .05). Mean anti-hypertensive dosage decreased to
1.4  0.8 DDD at one month (P < .05) and 0.6  0.8 DDD at last follow-up (P < .05). Mean esti-
mated glomerular filtration rate increased to 82  4.7 ml/min (P > .05) at one month and
91  4.1 ml/min (P < .05) at last follow-up. The dialysis-dependent patient no longer required
haemodialysis, and congestive heart failure resolved in all three patients.
Conclusions: Our data suggest that ARB with autologous saphenous vein graft is safe, effective
and durable in treating TARAS.
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48 R. Feng et al.Introduction peritoneal exposure. In all patients, aortic inflow wasTakayasu arteritis (TA) is a chronic idiopathic inflammatory
disease affecting the aorta and its major branches, leading
to segmental artery stenosis or occlusion.1e3 Takayasu
arteritis-induced renal artery stenosis (TARAS) may occur in
50e60% of TA patients,4,5 resulting in severe hypertension,
cardiac insufficiency, renal dysfunction or failure and
premature death.5,6
We performed aortorenal bypass (ARB) in 33 patients
with TARAS. This study was undertaken to clarify the
outcome of surgical renal revascularisation for TARAS, with
emphasis on the effects on hypertension and renal func-
tion. To our knowledge, this study included the largest
number of TARAS patients treated with ARB using the
autologous saphenous vein graft as reported in English.
Methods
Patients
Between 1997 and 2009, our institution treated 33 consecu-
tive TARAS patients with unilateral or bilateral ARB, includ-
ing nine males and 24 females with a mean age of 25  11.3
years (range, 8e54 years). TA was diagnosed according to
American College of Rheumatology criteria, which combines
three or more clinical features or arteriographic findings.7
Twenty-three patients had received corticosteroid and/or
immunosuppressant therapy. Three patients had previously
undergone aortocarotid bypass for carotid artery occlusion.
Seven patients developed restenosis of the renal arteries
within 1 year after receiving percutaneous angioplasty (PTA)
or PTA plus stenting in other hospitals.
Design
A retrospective chart review of these patients was con-
ducted, which had been approved by the hospital Institu-
tional Review Board. All patients or their parents gave
written consent to participate. Preoperative blood pressure
(BP), anti-hypertensive medications and renal function were
compared with those documented at 1 month after ARB and
last follow-up, respectively. In addition, angiographic find-
ings, erythrocyte sedimentation rate (ESR) and corticoste-
roid or immunosuppressant therapy data were collected.
BP was measured in limb arteries clinically free of or
least involved with TA. The anti-hypertensive dosage was
quantitated using the defined daily dose (DDD).8 Renal
function was determined with estimated glomerular filtra-
tion rate (e-GFR), which was calculated with the Cock-
crofteGault method based on serum creatinine (SCr)
concentration.9 Renal artery, aorta and its major branches
were assessed using computed tomography angiography
(CTA) or magnetic resonance angiography (MRA). Digital
subtraction angiography (DSA) was performed in patients
with equivocal results of the non-invasive imaging.
ARB procedure and follow-up
With autologous proximal saphenous vein graft, ARB was
conducted through abdominal midline incision and trans-located on the aorta 1e3 cm below the level of the renal
artery, which was accessed via a vertical diamond-shaped
incision. The diameter of proximal anastomosis was nearly
12 mm. For unilateral ARB, the proximal end of the graft
was cut into an oblique section and end-to-side anastomosis
was performed. For simultaneous bilateral ARB, a hori-
zontal diamond-shaped incision was made in the middle of
a single saphenous vein graft and side-to-side anastomosis
was performed (Fig. 1). Outflow was located on a healthy or
relative healthy segment of renal artery trunk. It was
determined by preoperative imaging and intra-operative
visual inspection or manual palpation. End-to-side anasto-
mosis was made between the graft and the renal artery
distal to stenosis, except one case in which end-to-end
anastomosis was performed.
All patients were given anticoagulation therapy with low-
molecular-weight heparin for 1 week after surgery. Then,
patients took anti-platelet drugs, such as aspirin or ticlopi-
dine, for 1e3 years. Patients with active inflammation were
given an intravenous infusion of hydrocortisone during the
perioperative period, and then took oral prednisone for 3e6
months. A tapering dose was considered in patients, who
had clinical and laboratory responses to treatment. The
anti-hypertensive dosage was adjusted, according to post-
operative BP levels. All patients were routinely followed up
at 1, 3 and 12 months after surgery, then annually.
Analysis and statistics
Treatment efficacy for hypertension was assessed according
to a modification of the 1987 Renal Working Group
guidelines:10
(1) cure: no anti-hypertensive medications were required,
BP was <140/90 mmHg;
(2) improvement: diastolic BP <90 mmHg and/or systolic
BP <140 mmHg or at least 15 mmHg reduction in dia-
stolic BP on the same or reduced anti-hypertensive
dosage; and
(3) failure: neither of the above two criteria were met.
In additional, an increase or decrease in e-GFR
10 ml mine1 was defined as improvement or failure of
renal function. Any smaller change in e-GFR indicated
stabilisation of renal function.
All the results were analysed using Statistical Package for
Social Sciences (SPSS 18.0) (SPSS Inc., Chicago, IL, USA).
Continuous variables are expressed as mean  standard
errors of the mean (SEM), and mean values were compared
with repeated measures analysis of variance (ANOVA).
Significance was attributed at P < 0.05. Cumulative patency
rates of the grafts were estimated by KaplaneMeier anal-
ysis. The life-table method was used to analyse the effects
of various factors on primary patency rate.
Results
Major clinical manifestations before ARB are shown in
Table 1. All patients showed severe hypertension (mean BP,
175  26/100  19 mmHg; mean anti-hypertensive dosage,
Figure 1 Schematic diagram of aortorenal bypass to treat TARAS: (A) Unilateral ARB. (B)e(D) Bilateral ARB using a single
saphenous vein graft. (B. Front view; C. Top view; D. Directions of the diamond-shaped incisions of the aorta and the saphenous
vein graft).
Table 1 Major clinical manifestations of patients
(n Z 33).
Clinical manifestation n %
Severe hypertension 33 (100)
Congestive heart failure 3 (9)
Renal function
CKD stage I 17 (52)
CKD stage II 10 (30)
CKD stage III 4 (12)
CKD stage IV 1 (3)
CKD stage V 1 (3)
Erythrocyte sedimentation rate
20 mm/h 29 (88)
>20 mm/h 4 (12)
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secondary to left-ventricular dysfunction. According to
chronic kidney disease (CKD) staging,11 renal functions from
stage I to V were found in 17, 10, four, one and one
patients, respectively. Mean e-GFR was 78  5.1 ml mine1.
One patient was dialysis-dependent. Mean ESR was
16  5 mm he1. Four patients with elevated ESR, including
three complicated by congestive heart failure and one
complicated by renal failure, underwent semi-urgent ARB.
They showed systemic inflammatory features in various
degrees. ESR at the time of intervention was less than
20 mm he1 in other cases.
Angiographic imaging before ARB showed 10 cases of
single left TARAS, 14 cases of single right TARAS and nine
cases of bilateral TARAS. All stenotic lesions were located
around the ostia of renal artery, except one case with
complete occlusion throughout the renal artery trunk. In
three of nine patients with bilateral TARAS, collateral
circulation formed between the inferior mesenteric artery
and the left renal artery (Fig. 2), and we did not intervene
with these three left renal arteries. Fourteen patients had
combined aortic stenosis above or at the level of the renal
artery. One patient with 80% stenosis underwent PTA of the
suprarenal aorta to reduce the degree of stenosis to 40%,
prior to bypass surgery. Aortic stenosis in the remaining 13
patients was <50% and no intervention was carried out. No
renal artery aneurysm was found.
ARB was performed for 39 renal arteries, including 27
with unilateral ARB and six with bilateral ARB (Fig. 3). Nonephrectomy was performed. All patients were successfully
followed up with the help of a TARAS patients’ association.
Mean follow-up was 56  18 months (range, 12e146
months). The outpatients’ records for the recent 5 years
were available. In these 5 years, 21 (54%) newly diagnosed
patients did not undergo any interventions. Among them,
five cases rejected operation because of individual reasons,
and other 16 cases achieved satisfied anti-hypertension
efficacy by conservative therapy, without renal
dysfunction.
Figure 2 MRA after ARB showing bypass graft for the right
renal artery (arrow), and collateral circulation formed
between the left renal artery and the inferior mesenteric
artery (arrowhead).
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Immediate renal revascularisation was achieved in all
cases. No perioperative deaths occurred. Postoperative
morbidity (15%) included retroperitoneal haematoma
around the anastomosis (nZ 2), transient ischaemic attack
(nZ 1) and wound infection (nZ 2). Among the two cases
of retroperitoneal haematoma, one patient recovered
uneventfully after haematoma removal. The other suffered
from partial renal infarction, but follow-up result showed
no significant renal function impairment and no interven-
tion was carried out. The grafts and the distal renal arteries
were patent in both patients. In one patient, BP returned to
normal postoperatively and increased again at 1 week after
ARB. MRA showed occlusion and thrombosis of the bypass,
which was mainly due to an excessively long and distor-
tional graft.
At 1 month after ARB, mean BP and mean anti-hyper-
tensive dosage decreased to 139  15/85  13 mmHg
(P < 0.05) and 1.4  0.8 DDD (P > 0.05), respectively. The
efficacy of ARB on hypertension was cure in 10 (30%),
improvement in 20 (61%) and failure in three (9%) patients.
Mean e-GFR increased to 82  4.7 ml mine1 (P > 0.05). The
efficacy on renal function was improvement in seven (21%),
stabilisation in 20 (61%) and failure in six (18%) patients.
Ten days after ARB, the aforementioned dialysis-dependent
patient no longer required haemodialysis.Midterm to long-term results
All patients survived, and five patients conceived and
delivered after ARB. At last follow-up, mean BP decreasedto 136  19/80  8 mmHg (P < 0.05) and mean anti-
hypertensive dosage was reduced to 0.6  0.8 DDD
(P < 0.05). With respect to hypertension, cure was seen in
18 (55%), improvement in 13 (69%) and failure in two (6%)
patients. Congestive heart failure resolved in all three
patients. Mean e-GFR increased to 91  4.1 ml mine1
(P < 0.05). The effect on renal function was improvement
in 12 (36%) and stabilisation in 17 (52%) patients. In the
remaining four (12%) patients, the effect on renal function
was assessed as ‘failure’, but their e-GFR decreased to less
than 15 ml mine1 and SCr was <133 umol l1.
During follow-up, two (6%) graft occlusions and four
(12%) graft restenosis were documented respectively.
Except for the patient with thrombosis in the graft 1 week
after surgery, one patient experienced similar complication
3 months after ARB. Both patients were treated with anti-
hypertensive medications without further intervention, but
the effects were poor. Graft restenosis was revealed in four
patients at 1, 3, 4 and 5 years after ARB, respectively, with
or without the occurrence of uncontrolled hypertension. All
restenotic lesions were located on anastomosis and showed
features of intimal hyperplasia in imaging. These lesions
were eliminated successfully with PTA, and elevated BP
gradually regressed. Except for one patient who developed
restenosis 6 months after PTA and declined a repeated PTA,
no restenosis has yet occurred in the remaining three
patients. Among the four patients with active inflammation
at the time of ARB, two graft restenosis developed and
were successfully treated with PTA. In the six patients who
underwent bilateral ARB, no restenosis was found. In the
seven patients who experienced restenosis after endovas-
cular treatment, no restenosis occurred after ARB. In
addition, mild aneurysm-like dilation at the distal anasto-
mosis was found in two cases at 2 and 3 years after ARB,
respectively. No significant increase in diameter was found
at last follow-up. During follow-up, no significant graft
elongation was identified, and initial aortic stenosis
remained stable.
The cumulative patency rates by KaplaneMeier analysis
are shown in Fig. 4. Primary patency rate of the renal grafts
at 1, 3 and 5 years was 92%, 89% and 79%, respectively. The
primary assisted patency rates were 95%, 95% and 91%,
respectively, and secondary patency rates also were 95%,
95% and 91%, respectively. The results showed that
elevated ESR at the time of surgery was a factor negatively
affecting primary patency rate (Wilcoxon (Gehan) statistic
value Z 4.856, df Z 1, PZ 0.028). Freedom from revision
at 5 years was 79% in patients with quiescent TA and 48% in
patients with active TA, respectively.Discussion
Although TARAS is considered a benign self-limiting disease,
aggressive intervention has been widely accepted, espe-
cially for the patients complicated by renal function
impairment and congestive heart failure. Most current
studies of surgical revascularisation for TARAS were con-
ducted in the Far East and South Asia.12e15 These studies
adopted different diagnostic criteria of TA, or combined TA
and other diseases, such as fibromuscular dysplasia. Some
studies did not separately analyse the results for TARAS
Figure 3 MRA before and 3 years after bilateral ARB using a single saphenous vein graft: (A) Bilateral TARAS (arrow). (B) and (C)
Bilateral bypass grafts (arrow). (B. Front view; C. Top view).
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struction with endovascular therapy and nephrectomy.
Some studies only focussed on the outcomes of hyperten-
sion regression and graft patency, but renal function was
ignored. Therefore, from the results the efficacy of surgical
reconstruction to treat TARAS is difficult to interpret.
Our study exclusively focussed on consecutive TARAS
cases treated with ARB, which may help clarify the thera-
peutic value of bypass surgery. In the present study, ARBFigure 4 KaplaneMeier analysis of graft patency after aor-
torenal bypass to treat TARAS. Solid line Z primary patency.
Dotted line Z primary assisted patency (including revised
restenotic grafts) and secondary patency (including revised
restenotic or occluded grafts).achieved patency rate, hypertension regression and cardiac
function improvement similar to those reported previously.
Moreover, we found that renal function can improve and
recover during follow-up, which is consistent with the
change in atherosclerotic renal artery stenosis treated with
ARB.16,17Surgical reconstruction or endovascular therapy
With a high initial success rate, endovascular procedures
seem attractive for TARAS.18,19 However, although
encouraging midterm to long-term results have been
reported sporadically,20,21 most believe that the restenosis
after angioplasty or stenting is common. Bayrak et al.19
performed PTA in 12 TARAS patients with a technical
success rate of 100%, but restenosis was observed in five
patients during 55.7 months of follow-up. Tanaka et al.22
used the cutting balloon to treat TARAS in eight patients
and achieved a technical success rate of 100%. However,
restenosis was found in four patients at 6 months after PTA.
A possible reason for high incidence of restenosis is that the
endovascular procedures may cause severe intimal injury
and arouse an inflammatory repair reaction in the vessel
wall.19,22
Despite the lack of a large sample study comparing
surgical reconstruction and endovascular therapy, we
believe the incidence of restenosis after ARB is lower than
that after endovascular therapy. In addition, surgical
reconstruction is more suitable for long lesions and severe
stenosis or occlusion, with a broader indication than
endovascular therapy. Therefore, we prefer revascularisa-
tion surgery to treat TARAS. Meanwhile, we believe that
PTA is an effective treatment for restenotic lesions after
ARB.
However, the invasion of the surgical reconstruction
must be recognised. Furthermore, in cases of restenosis or
occlusion, surgical adhesions and scars may handicap
52 R. Feng et al.resurgery. As to endovascular therapy, compared with the
higher restenotic rate, its minimal invasion and repeat-
ability may be more profitable. Therefore, we are consid-
ering a new treatment model for young patients with short-
segment stenosis at the inactive stage: endo e surg e endo.
These patients may undergo endovascular therapy first. If
restenosis occurs repeatedly, ARB will be performed. Once
stenosis reoccurs again after ARB, endovascular procedures
will be the first option again.Techniques of surgical reconstruction
Because of transmural inflammation, endarterectomy is not
recommended in patients with TARAS.23 Further, viscer-
alerenal artery bypass is not the preferred reconstruction
style because the patients can develop stenosis at other
visceral branches in the future. ARB arises directly from the
aorta and hardly impairs the blood supply to the other
visceral organs; therefore, ARB is considered as the best
surgical approach for TARAS.12
Previous studies have documented the development of
vasculitis, at anastomosis was the most important factor
leading to graft restenosis or occlusion. Consequently,
anastomosis should be placed in macroscopically normal
aorta and renal artery segments, or, at least avoid seriously
mural thickened segments from TA. For location of aortic
anastomosis, the aorta above the level of the renal artery
may better meet the haemodynamic requirements than
infrarenal aortic segment. However, anastomosis at
infrarenal aorta is more convenient and causes less injury
than at the suprarenal segment. Furthermore, based on our
experience, the infrarenal aorta is less seriously or exten-
sively involved by TA, and renal blood perfusion after ARB
improves without reference to suprarenal or infrarenal
aortic anastomosis. Weaver and colleagues13 reported 32
cases of ARB; of these, the graft inflow was located in the
infrarenal aorta in 19 cases, in the thoracic aorta in two
cases, in the suprarenal aorta in four cases, in the aortic
graft in five cases and in the visceral artery in two cases.
They found that graft patency was unaffected by the
position of the inflow. In the present study, ARB was per-
formed with infrarenal aortic anastomosis in all patients,
which achieved a patency rate to similar to that reported
by Weaver. Therefore, we believe infrarenal aortic anas-
tomosis is reliable. Of course, in such cases, patency of the
suprarenal aorta is important. Hence, concomitant aortic
reconstruction or aortic PTA in advance may be necessary.
However, unlike the experience of Weaver13 and Kieffer,14
we found a significantly lower percentage of patients who
required aortic reconstruction or PTA for a good inflow.
While continuous end-to-side sutures are usually adop-
ted for the aortaegraft anastomosis, end-to-end or end-to-
side sutures can be used for the grafterenal anastomosis.
Iwai et al.24 held that interrupted end-to-end sutures for
the distal anastomosis could improve the long-term patency
rate. In our study, preoperative MRA in one patient showed
a totally occluded trunk of the renal artery and a thin
accessory renal artery with a diameter of 1 mm. Renal
blood supply was successfully reconstructed in this patient
by ARB, using interrupted end-to-end sutures between the
graft and the accessory renal artery. The luminal diameterof the accessory renal artery gradually increased to 3 mm,
and the graft was patent 5 years after surgery.Other issues
Another issue concerns the history of TAand corticosteroid or
immunosuppressant therapy. Because of the differentiation
of inflammatory relapse and the variance of medical
therapy, it is difficult to determine the effects of medical
therapy on graft patency by statistic analysis. Nevertheless,
our study showed that active inflammation and elevated ESR
at the timeof ARBnegatively impactedprimary patency. This
finding is consistent with several previous reports.25,26
Although surgery should usually be avoided when the
disease is active, revascularisation may have to be consid-
ered in patients with malignant hypertension or rapidly
progressing renal failure.27 In such cases, besides anti-
coagulation and anti-platelet therapy, corticosteroid and
immunosuppressant should be given to inhibit an inflam-
matory reaction and prevent or alleviate restenosis.27,28
Even though the incidence of restenosis is high, the
problem can be resolved with endovascular procedures.
Anastomotic aneurysms may occur after bypass surgery
using the autologous vein graft. In the present study, two
cases of mild aneurysm-like dilation at anastomosis were
found. Miyata et al.29 reported an 8.5% incidence of anasto-
motic aneurysm, and the complication was more common in
patients with aneurysmal TA. Anastomotic aneurysms may
rupture, endangering the kidney and the patient’s life. In such
patients, periodic graft assessment is absolutely necessary.Conclusions
ARB with autologous saphenous vein graft is a safe, effec-
tive and durable method for TARAS, providing demonstrable
improvements in BP control and renal and cardiac function.Acknowledgement
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